Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD30-positive Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01309789
What this trial is testing

Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Who this might be right for
Lymphoma, Large-Cell, AnaplasticLymphoma, NK-cellLymphoma, T-cell
Seagen Inc. 39
Early research (Phase 1)WithdrawnNCT03373305
What this trial is testing

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Who this might be right for
CD30-Positive Neoplastic Cells PresentFolliculotropic Mycosis FungoidesRecurrent Mycosis Fungoides+4 more
City of Hope Medical Center
Testing effectiveness (Phase 2)WithdrawnNCT02623920
What this trial is testing

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaMediastinal Large B-cell LymphomaGrey Zone Lymphoma+4 more
University of Arizona
Early research (Phase 1)WithdrawnNCT07453446
What this trial is testing

Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma

Who this might be right for
Relapsed or Refractory Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Testing effectiveness (Phase 2)Looking for participantsNCT02259556
What this trial is testing

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas

Who this might be right for
Hodgkin's LymphomaNon-Hodgkin's Lymphoma
Chinese PLA General Hospital 30
Testing effectiveness (Phase 2)Study completedNCT00947856
What this trial is testing

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

Who this might be right for
Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin
Seagen Inc. 110
Early research (Phase 1)Study completedNCT00634452
What this trial is testing

Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma

Who this might be right for
Hodgkin's Lymphomas
Bristol-Myers Squibb 22
Early research (Phase 1)Active Not RecruitingNCT04526834
What this trial is testing

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

Who this might be right for
Anaplastic Large Cell LymphomaPeripheral T Cell LymphomaExtranodal NK/T-cell Lymphoma+2 more
Tessa Therapeutics 21
Early research (Phase 1)Study completedNCT01026233
What this trial is testing

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Who this might be right for
Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin
Seagen Inc. 52
Testing effectiveness (Phase 2)Study completedNCT02497131
What this trial is testing

Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients

Who this might be right for
Lymphatic Diseases
Fondazione Italiana Linfomi - ETS 25
Early research (Phase 1)Active Not RecruitingNCT04288726
What this trial is testing

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Who this might be right for
Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeClassical Hodgkin Lymphoma
Baylor College of Medicine 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT03113500
What this trial is testing

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Who this might be right for
Adult T-Cell Leukemia/LymphomaAnaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-Positive+8 more
City of Hope Medical Center 48
Testing effectiveness (Phase 2)Study completedNCT04101331
What this trial is testing

Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

Who this might be right for
Peripheral T Cell LymphomaTransformed Mycosis Fungoides
Affimed GmbH 108
Early research (Phase 1)Not Yet RecruitingNCT07729397
What this trial is testing

Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)Hodgkin LymphomaPeripheral T-cell Lymphoma (PTCL)+2 more
The Methodist Hospital Research Institute 21
Testing effectiveness (Phase 2)Study completedNCT03192202
What this trial is testing

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Who this might be right for
Lymphoma, T-Cell, Cutaneous
Ahmed Sawas 18
Testing effectiveness (Phase 2)UnknownNCT05320081
What this trial is testing

Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma

Who this might be right for
LymphomaRelapse/Recurrence
Huazhong University of Science and Technology 30
Testing effectiveness (Phase 2)Ended earlyNCT05883449
What this trial is testing

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

Who this might be right for
Relapsed or Refractory Hodgkin LymphomaPeripheral T Cell Lymphoma
Affimed GmbH 25
Not applicableWithdrawnNCT01671813
What this trial is testing

Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly

Who this might be right for
Lymphoma
H. Lee Moffitt Cancer Center and Research Institute
Testing effectiveness (Phase 2)UnknownNCT05316246
What this trial is testing

Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma

Who this might be right for
NK/T Cell Lymphoma Nos
Shanghai Zhongshan Hospital 40
Early research (Phase 1)WithdrawnNCT04952584
What this trial is testing

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

Who this might be right for
Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeClassical Hodgkin Lymphoma
Baylor College of Medicine
Next Page